Even in Denmark — Novo Nordisk's residence marketplace — an software for Wegovy to get general public wellness insurance policies coverage was turned down on the grounds that its cost was incommensurate with its therapeutic price.Meantime, supply constraints could dampen Preliminary distribution in the market place forecast to become worthy of